Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study

被引:9
作者
Chen ZhenPing [1 ]
Li PeiJing [1 ]
Li Gang [1 ]
Tang Ling [1 ]
Zhen YingZi [1 ]
Wu XinYi [1 ]
Cheng XiaoLing [1 ]
Hung Luke Koon [2 ]
Blanchette Victor S [3 ]
Poon ManChiu [4 ]
Ding QiuLan [5 ]
Wu RunHui
机构
[1] Hematology Oncology Center, Beijing Children’s Hospital, Capital Medical University, Beijing Key Laboratory of Pediatric Hematology Oncology, National Key Discipline of Pediatrics, Ministry of Education, Beijing 100045, China
[2] Department of Medicine, Pediatrics and Oncology, and Southern Alberta Rare Blood and Bleeding Disorders Comprehensive Care Program, University of Calgary, Foothills Hospital and Calgary Health Region, Calgary, Alberta, T2N2T9, Canada
[3] Department of Pediatrics and Laboratory Medicine, and Hemophilia Clinic, Children’s Hospital of Eastern Ontario and University of Ottawa, Ottawa, Ontario, K1H 8L1, Canada
[4] Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
[5] Department of Pediatrics and Child Health Evaluative Sciences, Division of Hematology/Oncology, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, Ontario, M5G 1X8, Canada
关键词
Boys; Factor VIII; Hemophilia A; Pharmacokinetics;
D O I
暂无
中图分类号
R554.1 [];
学科分类号
1002 ; 100201 ;
摘要
Background: Although much attention has been paid to the pharmacokinetics (PKs) of different factor VIII (FVIII) concentrates in persons with hemophilia A (HA), limited information is available in young boys with severe HA. In this study, we aimed to assess the PK parameters of FVIII products in boys with severe HA in China.Methods: A total of 36 boys (plasma-derived [pd]-FVIII,n = 15; recombinant [r] FVIII,n = 21) were enrolled between January 2015 and May 2016 in Beijing Children’s Hospital. PK characteristics of FVIII products were studied according to a reduced 4-sampling time point design (1 h, 9 h, 24 h, and 48 h postinfusion).Results: The mean FVIII half-life (t1/2) was 10.99 ± 3 .45 h (range 5.52- 20.02 h), the meanin vivo recovery (IVR) was 2.01 ± 0.42 IU/dl per IU/kg (range 1.24–3.02 IU/dl per IU/kg) and mean clearance (CL) of FVIII is 4.34 ± 1.58 ml·kg?1·h?1 (range 2.29–7.90 ml·kg?1·h?1). We also analyzed the influence of several parameters that potentially modulate FVIII PK. The age was closely associated with FVIII half-life (R2 = 0.32,P< 0.01). The t1/2 of FVIII increased by 0.59 h per year. Besides age, von Willebrand factor antigen (VWF:Ag) also was associated with FVIII half-life (R2 = 0.52,P< 0.01). Patients with blood Group O had a shorter FVIII half-life than patients with non-O blood group (9.40 ± 0.68 h vs. 12.3 ± 0.79 h,t = 2.70,P= 0.01). The FVIII IVR correlated with age (R2 = 0.21,P< 0.01) and VWF:Ag level (R2 = 0.28,P< 0.01). CL rates were faster in young patients and in those with low-VWF:Ag levels. CL rates of FVIII are higher in blood Group O versus non-blood Group O persons (5.02 ± 0.38 vs. 4.00 ± 0.32 ml·kg?1·h?1,t= 2.53,P= 0.02).Conclusions: Chinese boys with severe HA have similar PK values to other ethnic groups and large differences in FVIII PK between individual patients. Age, blood group, and VWF:Ag levels are important determining factors for FVIII CL.
引用
收藏
页码:1780 / 1785
页数:6
相关论文
共 50 条
  • [31] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    Chur-Woo You
    Hee-Sook Son
    Hee Jin Kim
    Eui-Jeon Woo
    Soon-Ae Kim
    Haing-Woon Baik
    International Journal of Hematology, 2010, 91 : 784 - 791
  • [32] Cost analysis of plasma-derived factor VIII/von Willebrand factor versus recombinant factor VIII for treatment of previously untreated patients with severe hemophilia A in the United States
    Neufeld, Ellis J.
    Sidonio, Robert F., Jr.
    O'Day, Ken
    Runken, M. Chris
    Meyer, Kellie
    Spears, Jeffrey
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (08) : 762 - 769
  • [33] Mutation analysis of factor VIII in Korean patients with severe hemophilia A
    You, Chur-Woo
    Son, Hee-Sook
    Kim, Hee Jin
    Woo, Eui-Jeon
    Kim, Soon-Ae
    Baik, Haing-Woon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2010, 91 (05) : 784 - 791
  • [34] A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A
    Bolon-Larger, Magali
    Chamouard, Valerie
    Bressolle, Francoise
    Boulieu, Roselyne
    THERAPEUTIC DRUG MONITORING, 2007, 29 (01) : 20 - 26
  • [35] Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A
    Wu, Runhui
    Wang, Xiaoling
    Zhao, Xielan
    Cheng, Yanli
    Zhou, Zeping
    Sun, Jing
    Xu, Ming
    Li, Wenqian
    Xiao, Jianwen
    Yang, Fenge
    Chen, Yun
    Xu, Weiqun
    Huang, Jing
    Ma, Chuanrong
    Gai, Wenlin
    Xie, Liangzhi
    Yang, Renchi
    HAEMOPHILIA, 2022, 28 (06) : E199 - E208
  • [36] Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study
    Dobbelstein, Christiane
    Moschovakis, Georgios Leandros
    Tiede, Andreas
    ANNALS OF HEMATOLOGY, 2020, 99 (09) : 2105 - 2112
  • [37] Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh
    Tory, Sanzina Sadia
    Ghosh, Sujan
    Nazneen, Humayra
    Farhad, Nurul
    Islam, Salwa
    Hasan, Mohammad Jahid
    Biswas, Akhil Ranjan
    EJHAEM, 2024, 5 (01): : 39 - 46
  • [38] Genetic Characterization of the Factor VIII Gene in a Cohort of Colombian Patients with Severe Hemophilia A with Inhibitors
    Doncel, Samuel Sarmiento
    Mosquera, Gina Alejandra Diaz
    Pelaez, Ronald Guillermo
    Cortes, Javier Mauricio
    Rico, Carol Agudelo
    Cadavid, Francisco Javier Meza
    Plazas, Nelson Ramirez
    Amar, Ivan Alfredo Perdomo
    Siado, Jorge Enrique Pena
    Rey, Fabian Andres Parrado
    Montano, Cesar Alberto
    Villadiego, Alexys Maza
    HEMATOLOGY REPORTS, 2022, 14 (02) : 149 - 154
  • [39] Recombinant single-chain factor VIII in severe hemophilia: Long-term safety and efficacy in previously treated patients in the AFFINITY extension study
    Mahlangu, Johnny
    Karim, Faraizah Abdul
    Stasyshyn, Oleksandra
    Korczowski, Bartosz
    Salazar, Blanca
    Lucas, Samantha
    Suen, Amy
    Goldstein, Brahm
    Chung, Thomas
    Pabinger, Ingrid
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2022, 6 (02)
  • [40] Immunogenicity and pharmacokinetic studies of recombinant Factor VIII containing lipid cochleates
    Kosloski, Matthew P.
    Peng, Aaron
    Varma, Prashant R.
    Fathallah, Anas M.
    Miclea, Razvan D.
    Mager, Donald E.
    Balu-iyer, Sathy V.
    DRUG DELIVERY, 2011, 18 (04) : 246 - 254